Clinical study "common" name (formal title)	Number of enrollees (per protocol [PP]/intent-to-treat [ITT])	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year completed	Primary publication	Full study treatment protocol
EVEREST II (Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial)	322 patients from Hong Kong, Japan, South Korea, Malaysia, Singapore, Taiwan, and Thailand	Novartis NCT01846273	2017	EVEREST II (Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy [PCV] Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy) Lim TH, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020; 138(9):935-942. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2768203